Verona Pharma (VRNA) to Release Earnings on Monday

Verona Pharma (NASDAQ:VRNA) is scheduled to be issuing its quarterly earnings data before the market opens on Monday, November 4th. Analysts expect the company to announce earnings of ($0.44) per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

Verona Pharma (NASDAQ:VRNA) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.53). During the same quarter in the previous year, the company posted ($0.11) earnings per share. On average, analysts expect Verona Pharma to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Verona Pharma Trading Up 3.1 %

Shares of VRNA opened at $34.98 on Friday. The stock has a fifty day moving average price of $30.61 and a two-hundred day moving average price of $22.09. The company has a debt-to-equity ratio of 0.72, a quick ratio of 8.61 and a current ratio of 8.61. Verona Pharma has a 52-week low of $11.39 and a 52-week high of $35.62. The company has a market cap of $2.80 billion, a price-to-earnings ratio of -22.71 and a beta of 0.44.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Truist Financial upped their price objective on Verona Pharma from $38.00 to $44.00 and gave the company a “buy” rating in a report on Wednesday, October 9th. Wells Fargo & Company assumed coverage on Verona Pharma in a report on Thursday, October 3rd. They issued an “overweight” rating and a $50.00 price objective for the company. Canaccord Genuity Group upped their price objective on Verona Pharma from $35.00 to $37.00 and gave the company a “buy” rating in a report on Monday, July 22nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $36.00 price objective on shares of Verona Pharma in a report on Tuesday, October 1st. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $39.33.

Insider Buying and Selling at Verona Pharma

In other news, CFO Mark W. Hahn sold 249,728 shares of the stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $4.38, for a total transaction of $1,093,808.64. Following the transaction, the chief financial officer now owns 14,089,960 shares in the company, valued at approximately $61,714,024.80. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, CFO Mark W. Hahn sold 249,728 shares of the stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $4.38, for a total transaction of $1,093,808.64. Following the transaction, the chief financial officer now owns 14,089,960 shares in the company, valued at approximately $61,714,024.80. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO David Zaccardelli sold 245,784 shares of the stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $4.38, for a total value of $1,076,533.92. Following the sale, the chief executive officer now directly owns 15,004,920 shares in the company, valued at $65,721,549.60. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 868,840 shares of company stock worth $3,805,519 over the last 90 days. Company insiders own 4.80% of the company’s stock.

About Verona Pharma

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.